G
Genmedica Therapeutics
Barcelona-based development-stage biotechnology company focused on type 2 diabetes
About Genmedica Therapeutics
Genmedica Therapeutics, established in Barcelona, Spain in 2004, operated as a biotechnology firm focused on developing treatments for type 2 diabetes. The company was co-founded by Antonio Zorzano, a researcher and coordinator of the Molecular Medicine Programme at IRB Barcelona. This connection highlights the company's foundation in robust scientific research.
The core of Genmedica's strategy was its proprietary OSIF platform, engineered to create dual-action, small molecule therapeutics. These molecules were designed to combat both oxidative stress and inflammation, two key factors in metabolic diseases. The business model centered on the discovery and progression of these proprietary chemical entities through the drug development pipeline, with the ultimate goal of offering improved therapeutic options to diabetic patients.
Throughout its operational history, the company successfully raised approximately $20.9 million over four funding rounds, attracting institutional investors such as Asclepios Bioresearch, Ferrer, and Caixa Capital Risc. A significant milestone was a €12 million Series B investment in 2012 from Asclepios Bioresearch, intended to fund the advancement of a diabetes drug into clinical trials. The company's lead candidate reached phase II trials, and it had two other candidates in early-stage testing for diabetes and obesity. Despite these developments, Genmedica Therapeutics is now considered a deadpooled company.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCEquity / VC | Dec 2015 | $1.9M | $7.5M | Undisclosed | — |
| EARLY VCEquity / VC | Feb 2014 | $1.1M | $4.4M | Undisclosed | — |
Growth signals
Latest recorded traffic for Genmedica Therapeutics is 90 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Genmedica Therapeutics in the Barcelona ecosystem
The Genmedica Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Criteria Venture Tech- ABAsclepios Biosearch
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genmedica Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genmedica Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









